---
run_id: halo-evidence-vs-diagnosis-validation-v7-famous-sources-supplied-08
created: 2026-05-23
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v7
benchmark_version: halo-evidence-vs-diagnosis-validation-v7-v1
model_condition: famous_sources_supplied
run_number: 8
model_name: gemma4:31b
model_id: gemma4:31b
model_snapshot: Ollama model ID 6316f0629137
runtime: Ollama local HTTP server; version 0.24.0
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 32768
seed: 802
prompt_source: condition packet (famous_sources_supplied) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 5a42e17859b4a23ae36d2682474f8d0369ffc492c200375fd79a14bf3b322262
source_packet: a name-level list of famous source titles and authors, then the frozen Advisor prompt; no claims, summaries, source cards, or tension card - see run-packet.md
source_packet_sha256: a8f837584b6b87efa42fb92f178885d67f9a6373379ee1ede9671b0a54d4d2f8
condition_packet_sha256: a8f837584b6b87efa42fb92f178885d67f9a6373379ee1ede9671b0a54d4d2f8
output_file: model-outputs/famous_sources_supplied-08.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - famous_sources_supplied (run 08)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v7-v1`, condition `famous_sources_supplied`, run 8 of 8. Real local-model run: `gemma4:31b` via Ollama, seed 802, on the frozen condition packet.

## Output

**Recommendation**
Recommend the **targeted evidence pass**.

**Why**
The current "upbeat story" is a textbook example of the **Halo Effect**: leadership is attributing a rise in revenue to a successful product strategy, when the evidence suggests the revenue is actually being "bought" through short-term discounts and the influence of account managers.

The core of the problem is a disconnect between *vanity metrics* (overall usage up 44%, NRR up) and *actionable metrics* (front-line reviewer retention at only 31%). In a B2B workflow tool, the "Job to be Done" is not "using the software," but "completing a compliance task that survives an audit." The evidence shows that for the most critical segment (regulated insurance), the product fails this fundamental requirement.

Scaling now (Option 1) would be "Bad Strategy" because it ignores the crux of the problem—lack of product-market fit for the actual end-user—and instead doubles down on a flawed distribution model. Narrowing the focus to regulated insurance (Option 3) is premature; you cannot pivot to a specific niche until you have instrumented the behavior to know if "explainability" is a solvable feature gap or a fundamental architectural flaw. The evidence pass is the only option that treats the current revenue bump as a hypothesis to be tested rather than a victory to be scaled.

**The Strongest Reason Against It**
The primary risk is **political and momentum-based**. The CEO and Board are currently experiencing a high from the "upbeat story." Recommending a pause on discounts and a "evidence pass" will be perceived as braking during a perceived acceleration. In a B2B environment, pausing a "market wedge" can be seen as a lack of aggression or a failure to capitalize on a window of opportunity, potentially damaging your internal credibility with Sales leadership.

**Observable Evidence That Would Change My Mind**
I would shift my recommendation to **Option 1 (Scale Broadly)** if the "non-renewal letters" are revealed to be caused by factors entirely unrelated to Review Assist (e.g., budget cuts or mergers) AND if the 31% front-line retention rate is found to be acceptable for the specific "Job to be Done" (i.e., if the feature is a "low-frequency, high-value" tool rather than a daily workflow tool).

I would shift to **Option 3 (Narrow Focus)** if the evidence pass reveals that the "ops champions" in other segments are only using the tool for demos and that the *only* segment showing any organic, non-discounted appetite for the product is the regulated insurance group, provided the "explainability" gap is identified as a discrete, solvable engineering task.
